Substance / Medication

Cidofovir

Overview

Active Ingredient
cidofovir
RxNorm CUI
83171

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:
Intralesional Cidofovir: A Systematic Review of Administration Protocols and Long-term Recurrence Rates in Adult and Juvenile Recurrent Respiratory Papillomatosis.
Pamonag Michael Zambarrano, Seery Alexis Marie, Omari Ahmad Issa Al et al. · J Voice · 2025
PMID: 37620175Meta-Analysis
Intralesional cidofovir vs. bevacizumab for recurrent respiratory papillomatosis: a systematic review and indirect meta-analysis.
Zagzoog Faisal H, Mogharbel Ahmed M, Alqutub Abdulsalam et al. · Eur Arch Otorhinolaryngol · 2024
PMID: 37831132Meta-Analysis
Systematic review of intralesional cidofovir dosing regimens in the treatment of recurrent respiratory papillomatosis.
Clamp Philip J, Saunders Michael W · Int J Pediatr Otorhinolaryngol · 2013
PMID: 23369614Meta-Analysis
Combined HPV 16 E2 and L1 methylation predict response to treatment with cidofovir and imiquimod in patients with vulval intraepithelial neoplasia.
Hurt Christopher Nicholas, Nedjai Belinda, Alvarez-Mendoza Carlos et al. · Cancer Biomark · 2022
PMID: 35912731RCTFull text (PMC)
The effect of low-dose cidofovir on the long-term outcome of polyomavirus-associated nephropathy in renal transplant recipients.
Wu Sheng-Wen, Chang Horng-Rong, Lian Jong-Da · Nephrol Dial Transplant · 2009
PMID: 19059933RCT
Cidofovir efficacy in recurrent respiratory papillomatosis: a randomized, double-blind, placebo-controlled study.
McMurray J Scott, Connor Nadine, Ford Charles N · Ann Otol Rhinol Laryngol · 2008
PMID: 18700421RCT
Effect of topical ophthalmic application of cidofovir on experimentally induced primary ocular feline herpesvirus-1 infection in cats.
Fontenelle Jennifer P, Powell Cynthia C, Veir Julia K et al. · Am J Vet Res · 2008
PMID: 18241028RCT

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Cidofovir (substance)
SNOMED CT
386894007
UMLS CUI
C0286079
RxNorm CUI
83171

Clinical Data

This intervention maps to 2 entities in the Ltrl knowledge graph.

2
Conditions
0
Biomarkers
0
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.